PL3468577T3 - Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera - Google Patents

Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera

Info

Publication number
PL3468577T3
PL3468577T3 PL17728263T PL17728263T PL3468577T3 PL 3468577 T3 PL3468577 T3 PL 3468577T3 PL 17728263 T PL17728263 T PL 17728263T PL 17728263 T PL17728263 T PL 17728263T PL 3468577 T3 PL3468577 T3 PL 3468577T3
Authority
PL
Poland
Prior art keywords
treatment
prion protein
alzheimer disease
dendrimer conjugates
dendrimer
Prior art date
Application number
PL17728263T
Other languages
English (en)
Inventor
Krzysztof NIEZNAŃSKI
Hanna NIEZNAŃSKA
Witold K. SUREWICZ
Krystyna SUREWICZ
Magdalena BANDYSZEWSKA
Original Assignee
Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Polskiej Akademii Nauk
Case Western Reserve University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Polskiej Akademii Nauk, Case Western Reserve University filed Critical Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Polskiej Akademii Nauk
Publication of PL3468577T3 publication Critical patent/PL3468577T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL17728263T 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera PL3468577T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
PCT/IB2017/052733 WO2017195131A1 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
EP17728263.9A EP3468577B1 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease

Publications (1)

Publication Number Publication Date
PL3468577T3 true PL3468577T3 (pl) 2022-02-14

Family

ID=59014670

Family Applications (2)

Application Number Title Priority Date Filing Date
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
PL17728263T PL3468577T3 (pl) 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera

Country Status (6)

Country Link
US (1) US10815292B2 (pl)
EP (1) EP3468577B1 (pl)
ES (1) ES2901053T3 (pl)
IL (1) IL262902B2 (pl)
PL (2) PL417159A1 (pl)
WO (1) WO2017195131A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112439074B (zh) * 2020-12-03 2022-09-13 浙江大学 可快速提高功能多肽亲和力的偶联物及其制备方法和应用
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128774A (en) 1994-03-07 2001-05-20 Dow Chemical Co Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof
KR19990029749A (ko) 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
PT1346041E (pt) * 2000-11-27 2007-06-05 Praecis Pharm Inc Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica.
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
WO2005095633A1 (en) * 2004-04-02 2005-10-13 Queen's University At Kingston A cell culture system for modelling serum amyloid a amyloidogenesis and identifying amyloid modulating compounds
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
US9217036B2 (en) * 2007-04-26 2015-12-22 Yale University Prion protein as a receptor for amyloid-β oligomers
WO2009041902A1 (en) 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
EP2885318A4 (en) * 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES

Also Published As

Publication number Publication date
EP3468577A1 (en) 2019-04-17
IL262902B2 (en) 2023-02-01
IL262902A (en) 2019-03-31
PL417159A1 (pl) 2017-11-20
WO2017195131A1 (en) 2017-11-16
US20190092837A1 (en) 2019-03-28
US10815292B2 (en) 2020-10-27
IL262902B (en) 2022-10-01
EP3468577B1 (en) 2021-09-15
ES2901053T3 (es) 2022-03-21

Similar Documents

Publication Publication Date Title
IL314312B1 (en) Pharmaceutical preparation containing deuterated lometaprone for the treatment of psychosis in Alzheimer's disease
IL285722A (en) Methods for treating alzheimer's disease
IL264641A (en) Acetyl-leucine for use in the treatment of neurodegenerative diseases
IL256175A (en) Using exosomes to treat the disease
IL247085B (en) Methods for treating Alzheimer's disease
PT3212233T (pt) Terapia combinada para o tratamento de doenças
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
HRP20182069T1 (hr) Farmaceutski pripravci za liječenje alzheimerove bolesti
ZA201605341B (en) Methods of treating alzheimer's disease
IL250990A0 (en) Materials for human care
SI3119911T1 (sl) Spojine za uporabo v zdravljenju alzheimerjeve pri pacientih z apoe4+/+
IL263188B (en) Treatment for Parkinson's disease
GB201512596D0 (en) Biomolecules involved in Alzheimer's disease
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
IL262902B (en) Prion protein-dendrimer conjugates for use in the treatment of Alzheimer's disease
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
HUE061056T2 (hu) Készítmény meddõség kezelésére nõi betegnél
SG11201607693WA (en) 6-substituted estradiol derivatives for the treatment of alzheimer's disease
GB201710410D0 (en) Inorganic polyphosphate formulations for use in the treatment of alzheimer disease
GB201603510D0 (en) Compositions for use in the treatment of neurological disease
ZA201807944B (en) Treatment for parkinson's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201414038D0 (en) Alzheimer's disease
GB201621398D0 (en) Treatment of emt-associated disease
GB201614863D0 (en) Alzheimer's disease